Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/250525
COMPARTIR / EXPORTAR:
logo share SHARE logo core CORE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE

Invitar a revisión por pares abierta
Título

Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naive and COVID-19 recovered individuals

AutorLozano-Ojalvo, Daniel CSIC ORCID; Cámara, Carmen; López-Granados, Eduardo; Nozal, Pilar; Pino-Molina, Lucía del; Bravo-Gallego, Luz Yadira; Paz-Artal, Estela; Pion, Marjorie; Correa-Rocha, Rafael; Ortiz, Alberto; López-Hoyos, Marcos; Erro Iribarren, Marta; Portoles, Jose; Rojo-Portoles, María Pilar; Ojeda, Gloria; Cervera, Isabel; González-Pérez, María; Bodega-Mayor, Irene; Montes-Casado, María; Portolés, Pilar; Pérez-Olmeda, Mayte; Oteo, Jesús; Sanchez-Tarjuelo, Rodrigo; Pothula, Venu; Schwarz, Megan; Brahmachary, Manisha; Tan, Anthony Tanoto; Le Bert, Nina; Berin, M. Cecilia; Bertoletti, Antonio; Guccione, Ernesto; Ochando, Jordi
Palabras claveCOVID-19
T-cell immunity
BNT162b2 vaccine
SARS-CoV-2
Fecha de publicación24-ago-2021
EditorElsevier BV
CitaciónCell Reports 36(8): 109570 (2021)
ResumenThe rapid development of mRNA-based vaccines against the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) led to the design of accelerated vaccination schedules that have been extremely effective in naive individuals.While a two-dose immunization regimen with the BNT162b2 vaccine has been demonstrated to provide a 95% efficacy in naive individuals, the effects of the second vaccine dose in individuals who have previously recovered from natural SARS-CoV-2 infection has not been investigated in detail. In this study, we characterize SARS-CoV-2 spike-specific humoral and cellular immunity in naive and previously infected individuals during and after two doses of BNT162b2 vaccination. Our results demonstrate that, while the second dose increases both the humoral and cellular immunity in naive individuals, COVID-19 recovered individuals reach their peak of immunity after the first dose. These results suggests that a second dose, according to the current standard regimen of vaccination, may be not necessary in individuals previously infected with SARS-CoV-2.
Versión del editorhttps://doi.org/10.1016/j.celrep.2021.109570
URIhttp://hdl.handle.net/10261/250525
DOI10.1016/j.celrep.2021.109570
ISSN2211-1247
Aparece en las colecciones: (PTI Salud Global) Colección Especial COVID-19
(CIB) Artículos




Ficheros en este ítem:
Fichero Descripción Tamaño Formato
PIIS2211124721010044.pdf1,12 MBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo

CORE Recommender

SCOPUSTM   
Citations

71
checked on 23-mar-2024

WEB OF SCIENCETM
Citations

74
checked on 24-feb-2024

Page view(s)

95
checked on 28-mar-2024

Download(s)

227
checked on 28-mar-2024

Google ScholarTM

Check

Altmetric

Altmetric


Este item está licenciado bajo una Licencia Creative Commons Creative Commons